Abstract:Abstract Despite the development of new immunotherapy strategies, lung cancer remains the leading cause of cancer-related deaths. One of the reasons is attributed to the persistence of cancer stem cells (CSCs) within the tumor, contributing to drug resistance, dormancy and metastatic spread. To eradicate CSCs, iPSC-based vaccination represents a novel approach based on the paradigm that CSCs and iPSCs share common tumor associated antigens (TAAs) with the ability to elicit a strong anti-tumor immune response.We previously showed that induced allogeneic pluripotent stem cells (miPSCs), combined with a histone deacetylase inhibitor (HDACi), induced a major reduction of tumor growth and metastatic spread to lungs in an aggressive triple negative breast cancer model (4T1) in syngeneic mice. We report here the use of the same protocol in a lung carcinoma model using LLC1 cell line in combination with an anti-CTLA4 antibody. We compared the effectiveness of allogenic miPSCs treatment alone or with an anti-CTLA4 mouse antibody on mice-bearing LLC1-Luc tumors (mean+se: 17,5+0,6 mm3). Five mice received 5 subcutaneous (SC) injection of 2 × 106 miPSCs, 5 mice received 3 intraperitoneal injections of anti-CTLA4 antibody at 5mg/kg and 5 mice were treated with the combinatory regimen (miPSCs and anti- CTLA4) with the same doses. In addition, all treated mice received a HDACi in the drink water throughout the experience.After 24 days, all tumor volumes from the 3 groups were significantly reduced compared to the control mice receiving only PBS. We obtained a reduction of 72% (p=0.007) and 74% (p=0.009) respectively for the mice treated solely with miPSCs or anti-CTLA4. An important synergic effect was obtained for the mice treated with miPSCs and anti- CTLA4 with a reduction of the tumor size by 92% (p=0.005) compared to the control mice. We also found a significant inhibition of metastatic spread to lungs for the 3 groups that was more pronounced in mice receiving the combination treatment with a significant reduction of 91 % compared to the control group. All these therapeutic effects were correlated with a significant increase of CD4+ and CD8+ cells that was more pronounced in mice receiving the combinatory regimen.We also have performed single-cell RNA sequencing analysis (10x Genomics) of LLC1 tumors treated with miPSCs and anti- CTLA4 compared to mice treated with monotherapy and untreated mice. T-distributed stochastic neighbor embedding plot reveals distinct clusters of stromal and immune cells across tumors with a significant upregulation of CD8+ and CD4+ T cells in mice receiving the combinatory regimen.Overall, these results demonstrate for the first time the clinical relevance of using an off-the-shelf allogeneic iPSC-based vaccine combined with an anti-CTLA4 antibody as a new anti-cancer immunotherapy strategy against aggressive non-small cell lung cancer (NSCLC) with metastatic potential. Citation Format: Frank Griscelli, Diana Chaker, Noufissa Oudrhiri, Christophe Desterke, Ali G. Turhan, Annelise Bennaceur Griscelli. Induced pluripotent stem cell (iPSC) based vaccines potentializes anti-CTLA4 immune response in a murine lung carcinoma model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2780.

Antitumor Activity of Pluripotent Cell-Engineered Vaccines and Their Potential to Treat Lung Cancer in Relation to Different Levels of Irradiation

Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells

Irradiation increases the immunogenicity of lung cancer cells and irradiation-based tumor cell vaccine elicits tumor-specific T cell responses in vivo.

Superior Anti-Tumor Protection and Therapeutic Efficacy of Vaccination with Dendritic Cell/Tumor Cell Fusion Hybrids for Murine Lewis Lung Carcinoma

Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime

Abstract 2780: Induced pluripotent stem cell (iPSC) based vaccines potentializes anti-CTLA4 immune response in a murine lung carcinoma model

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model

Expression Levels of a Gene Signature in Hipsc Associated with Lung Adenocarcinoma Stem Cells and Its Capability in Eliciting Specific Antitumor Immune‐response in a Humanized Mice Model

Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects

Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy

Combined Radiation Therapy and Dendritic Cell Vaccine for Treating Solid Tumors with Liver Micro‐metastasis

In vitro induction of anti‐lung cancer immune response by the A549 lung cancer stem cell lysate‐sensitized dendritic cell vaccine

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy

A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity

Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine

Exosome-based cancer vaccine for prevention of lung cancer

Antitumor Effect of Lung Cancer Vaccine with Umbilical Blood Dendritic Cells in Reconstituted Scid Mice

Spatiotemporal Controllable Sono‐Nanovaccines Driven by Free‐Field Based Whole‐Body Ultrasound for Personalized Cancer Therapy

Induction of therapeutic immunity and cancer eradication through biofunctionalized liposome-like nanovesicles derived from irradiated-cancer cells

[New Strategy of Cancer Immunotherapy: Irradiation or Chemotherapeutics-Induced Lymphopenia Combined with Immune Reconstitution and Tumor Vaccine].